ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 4, 2018
Dividend Increases/Decreases for the Week Ending May 4
Let's take a look at companies that raised/lowered their dividend this week.
May 3, 2018
Gilead Sciences at the Crossroads; HIV and Oncology Franchises Promising
Image Source: Gilead Sciences' first-quarter 2018 results. The loss of a key revenue-generating molecule is a tough, yet oftentimes manageable, portion of a pharma entity’s overall life cycle. Gilead Sciences is in the midst of a key turnaround as the loss of revenue from its Hepatitis C franchise is beginning to abate, while new novel treatments embark on the early stages of their respective revenue cycles. That said, we'd like to see traction in its HIV and oncology franchises, and perhaps the addition of a new franchise to the portfolio, or we will sour on the stock long-term.
May 3, 2018
Oil Majors Benefit from Higher Energy Resource Prices
Exxon Mobil, ConocoPhillips, and Chevron reported improved earnings and cash flow during the first quarter of 2018, thanks largely to higher realized energy resource pricing. The group may be better positioned for further bottom-line expansion moving forward as volume growth is expected to continue over the course of the year.
May 2, 2018
Waste Industry Collecting Cash
Pressures in the recycling business didn’t negate revenue growth across the municipal solid waste space during the first quarter of 2018, and the pace of operating-income and free-cash-flow expansion remains solid. Valuations could be more attractive, but dividends look strong, even though we’d like to see lower levels of financial leverage.
May 2, 2018
Apple’s Quarter Brings a Bushel of Positive News
Image Source: Aaron Yoo. Apple’s strength was on full display in its second quarter of fiscal 2018 as it beat expectations on a number of quarterly measures and delivered a significant dividend increase. The company remains one of our favorites on the market today. Our fair value estimate currently sits at $201 per share.
May 2, 2018
Optimizing Coverage
We're shifting our coverage around a bit to better allocate resources to areas that are of interest to you!
Apr 30, 2018
M&A Roundup: Sprint and T-Mobile Finally Official, Marathon Petroleum to Become Nation’s Largest Refiner
Image Source: Mike Mozart. A number of notable deals hit the wires over the weekend or Monday morning. Let's take a quick look. We expect to update our reports on the respective companies in the coming days.
Apr 30, 2018
Portfolio Diversification Begins at Alexion; Shares Cheap
Image Source: Alexion. We view the acquisition of differentiated, late-stage molecules at an attractive rate as the optimal use of free cash flow for many in the biotech industry. The finite commercial life of a patented drug forces continued innovation as near-total revenue erosion is a certainty once patent protection has lapsed. Let’s review some of the recent events at Alexion to gain a further understanding of the underlying trends affecting the business.
Apr 27, 2018
Dividend Growth Ideas Microsoft and Intel Deliver Strong Free Cash Flow
Microsoft and Intel continue to deliver robust levels of free cash flow, which are core drivers of their respective dividend strength.
Apr 27, 2018
GM and Ford Tune Up Operations for the Future of Automaking
Image Source: GM's first-quarter earnings report. The US auto behemoths continue to place a greater importance on efficient operations and the health of their bottom lines. The industry may be reaching a relative peak in terms of light vehicle production for this economic cycle, and the future of the auto landscape remains uncertain.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.